Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hong Kong Hospital Reform To Blur Public-Private Divide

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - In a bid to maximize the efficiency of its healthcare system, Hong Kong wants to blur the lines between public and private health providers

You may also be interested in...



AstraZeneca Hong Kong President Sian Ng On The Pros And Cons Of The Hong Kong Market: An Interview With PharmAsia News

Hong Kong is increasingly viewed, and judged, in the shadow of Mainland China, which has seen explosive growth in recent years and has become the top emerging markets priority for most Big Pharma. This perception, however, obscures the reality that Hong Kong remains an independent and vibrant market, where new drugs are often approved more quickly than on the mainland.

AstraZeneca Hong Kong President Sian Ng On The Pros And Cons Of The Hong Kong Market: An Interview With PharmAsia News

Hong Kong is increasingly viewed, and judged, in the shadow of Mainland China, which has seen explosive growth in recent years and has become the top emerging markets priority for most Big Pharma. This perception, however, obscures the reality that Hong Kong remains an independent and vibrant market, where new drugs are often approved more quickly than on the mainland.

Hong Kong Health Reforms Ignore Pharmaceutical Costs

HONG KONG - A proposed Health Protection Scheme in Hong Kong may not include coverage for medicines for serious or chronic diseases

Related Content

UsernamePublicRestriction

Register

SC077185

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel